Last reviewed · How we verify
Prevention of NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Nexium | esomeprazole | AstraZeneca | Proton pump inhibitor (PPI) | Potassium-transporting ATPase | 2001-02-20 | |
| Cytotec | misoprostol | Generic (originally Searle/Pfizer) | Prostaglandin E1 analog | Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin E2 receptor EP4 subtype | 1988-12-27 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- AstraZeneca · 1 drug in Prevention of NSAID-Induced Gastric Ulcer
- Generic (originally Searle/Pfizer) · 1 drug in Prevention of NSAID-Induced Gastric Ulcer
- Pfizer · 1 drug in Prevention of NSAID-Induced Gastric Ulcer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of NSAID-Induced Gastric Ulcer:
- Prevention of NSAID-Induced Gastric Ulcer treatment updates — RSS
- Prevention of NSAID-Induced Gastric Ulcer treatment updates — Atom
- Prevention of NSAID-Induced Gastric Ulcer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-nsaid-induced-gastric-ulcer. Accessed 2026-06-10.
Related
- Prevention of NSAID-Induced Gastric Ulcer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing